Celiac Disease Pipeline Insights: Analysis of Emerging Therapies, Key Pharma Players and Novel Approaches
Celiac disease pipeline report provides an analysis of 18+ key companies and 18+ key pipeline therapies. Larazotide by 9 Metres Biopharma represents the only Phase 3 therapeutic in development for celiac disease, with interim analysis expected in the first half of 2021.
Celiac disease pipeline report provides an analysis of 18+ key companies and 18+ key pipeline therapies. Larazotide by 9 Metres Biopharma represents the only Phase 3 therapeutic in development for celiac disease, with interim analysis expected in the first half of 2021.
DelveInsight’s “Celiac Disease Pipeline Insights, 2021” report puts forward detailed insights into the present clinical development landscape of the therapeutic agents and upcoming trends owing to the launch of the therapies.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The report is designed to help its clients to have a clearer understanding of the Celiac disease pipeline landscape, key companies working to develop Celiac disease treatments, novel therapies under clinical trials and investigations segmented into stages of their clinical development, therapeutic assessment on the basis of RoA, MoA and so on.
Gain rich insights into recent happenings, NDA approvals (if any), collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details and product development activities in the Celiac disease domain.
Want to learn more about the leading candidates in different clinical stages of trials? Reach out @ Celiac Disease Pipeline Insights
Celiac Disease: Overview
Celiac disease is an autoimmune disorder that occurs in individuals who develop an immune reaction to gluten. Celiac disease symptoms in adults include weight loss, abdominal bloating, constipation or diarrhea, vomiting, and pale, fatty, foul-smelling stools.
Celiac disease gets genetically inherited and is diagnosed with the help of blood tests. People suffering from Celiac disease are at two times greater risk of developing coronary artery disease and four times higher risk of getting bowel cancers.
At present, the only option available to the patients for its treatment is lifelong adherence to a strict gluten-free diet as there is no available Celiac disease cure. However, the scientific community and pharmaceutical companies are energetically driving the development of pipeline therapies forward.
Source: Globenews Wire